Table 1.
CAR-NK cell clinical trials.
| Cancer type | |
|---|---|
| Anti-CD22 CAR NK cells | Refractory B-cell lymphoma |
| Anti-CD19 CAR NK cells | Refractory B-cell lymphoma |
| Anti-CD19/CD22 CAR NKCELLS | Refractory B-cell lymphoma |
| Anti-Mesothelin CAR NK cells | Epithelial ovarian cancer |
| Anti-PSMA CAR NK cells | Castration-resistant prostate cancer |
| CAR-NK cells targeting NKG2D ligands | Solid tumors |
| ROBO1 CAR-NK cells | Solid tumors |
| BCMA CAR-NK 92 cells | Multiple myeloma |
| Anti-CD33 CAR-NK cells | Acute myelogenous leukemia, AML, AML with maturation, AML without maturation |
| Anti-CD19 CAR-NK cells | ALL, CLL, Follicular lymphoma, Mantle cell lymphoma, B-cell prolymphocytic leukemia, Diffuse large cell lymphoma |
| BiCAR-NK cells (ROBO1 CAR-NK cells) | Pancreatic cancer |
| BiCAR-NK/T cells (ROBO1 CAR-NK/T cells) | Malignant tumor |
Current clinical trials that involved CAR-NK cells. CD22 and CD19, B cell receptors; Mesothelin, protein expressed in mesothelial cells; PSMA, prostate-specific membrane antigen; ROBO1, roundabout homolog 1; BCMA, B-cell maturation antigen; CD33, myeloid cell antigen; AML, acute myeloid leukemia; CLL, chronic lymphocytic leukemia.